Results 251 to 260 of about 20,264 (293)
Some of the next articles are maybe not open access.
Physiologically Based Pharmacokinetic Modeling: Principles and Applications
Journal of Pharmaceutical Sciences, 1983Concentrations of bromophenol blue (I) in plasma, urine, and bile were determined spectrophotometrically after intravenous bolus injections and infusions in rats. The plasma concentrations were found to decrease monoexponentially after all doses except the highest, where the decrease was biexponential.
L E, Gerlowski, R K, Jain
openaire +2 more sources
Physiologically based pharmacokinetic models for anticancer drugs
Cancer Chemotherapy and Pharmacology, 1979The rationale and history of the development of physiologically based pharmacokinetic models are briefly reviewed in this paper. The methods of model construction and the previous application of this type of model to anticancer drugs are discussed. Future research should be focused on the following areas: (1) interspecies scaling, (2) the effects of ...
H S, Chen, J F, Gross
openaire +2 more sources
Physiologically based pharmacokinetic modelling
2003AbstractThis chapter provides a general introduction to physiologically based pharmacokinetic (PBPK) modeling of exposure in occupational and environmental epidemiological studies. It describes models that could be used for the assessment. It provides various examples and references.
George Loizou, Martin Spendiff
openaire +1 more source
Physiologically-Based Pharmacokinetic Modeling
Drug Information Journal, 1994Physiologically-based pharmacokinetic (PB-PK) models attempt to provide both a realistic anatomic description of the animal to which a drug or toxic chemical has been administered and a biologically accurate representation of the physiological pathways for chemical storage, metabolism, and elimination in the animal.
openaire +1 more source
Physiology-based pharmacokinetic modeling: ready to be used
Drug Discovery Today: Technologies, 2004Physiology-based pharmacokinetic (PBPK) modeling is well recognized as a technology for mechanistically simulating and predicting the fate of substances in a mammalian body. Today, the demand for this methodology is higher than ever. The pharma industry and regulatory agencies are looking for new methods, which help to speed up and increase the ...
Walter, Schmitt, Stefan, Willmann
openaire +3 more sources
Structural Identifiability of Physiologically Based Pharmacokinetic Models
Journal of Pharmacokinetics and Pharmacodynamics, 2006When starting a project in drug kinetics it is necessary to test a priori whether there is sufficient information in the experimental input-output design to estimate unique values of internal rate constants. This is an important test if the pharmacokinetics of a drug are to be characterised in some way by the parameter values estimated from the ...
openaire +2 more sources
A physiologically based model for tramadol pharmacokinetics in horses
Journal of Theoretical Biology, 2017This work proposes an application of a minimal complexity physiologically based pharmacokinetic model to predict tramadol concentration vs time profiles in horses. Tramadol is an opioid analgesic also used for veterinary treatments. Researchers and medical doctors can profit from the application of mathematical models as supporting tools to optimize ...
Abbiati, Roberto Andrea +4 more
openaire +4 more sources
Physiologically-Based Pharmacokinetic Modeling and Bioactivation of Xenobiotics
Toxicology and Industrial Health, 1994This paper describes the development and implementation of physiologically-based pharmacokinetic (PB-Pk) models to examine the disposition of xenobiotics and their bioactivation. In a PB-Pk model, the structure of the model is based, to as great extent as practicable, on the actual physiological and biochemical structure of the animal system being ...
H J, Clewell, M E, Andersen
openaire +2 more sources
A Physiologically Based Pharmacokinetic Model of Inorganic Arsenic
Regulatory Toxicology and Pharmacology, 1999This study presents a physiologically based pharmacokinetic model of inorganic arsenic disposition in humans. The model focuses on short-term exposures by the oral route. The model considers the four circulating species (AsIII, AsV, and two metabolites, i.e., monomethylarsenic (MMA) and dimethylarsenic (DMA)) in tissue groups.
openaire +2 more sources
Physiologically Based Pharmacokinetic Modeling of Arsenic in the Mouse
Journal of Toxicology and Environmental Health, Part A, 2004A remarkable feature of the carcinogenicity of inorganic arsenic is that while human exposures to high concentrations of inorganic arsenic in drinking water are associated with increases in skin, lung, and bladder cancer, inorganic arsenic has not typically caused tumors in standard laboratory animal test protocols.
P Robinan, Gentry +5 more
openaire +2 more sources